Thursday, February 2, 2023
Google search engine
HomeMarketResultsDay One Biopharmaceuticals (NASDAQ:DAWN) Given New $45.00 Price Target at Piper Sandler

Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $45.00 Price Target at Piper Sandler


Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) had its worth goal lifted by analysts at Piper Sandler from $40.00 to $45.00 in a analysis report issued to shoppers and buyers on Sunday, The Fly studies. Piper Sandler’s goal worth would point out a possible upside of 110.87% from the corporate’s present worth.

DAWN has been the subject of a number of different studies. HC Wainwright assumed protection on shares of Day One Biopharmaceuticals in a analysis report on Thursday, December fifteenth. They issued a “purchase” ranking and a $35.00 worth goal on the inventory. Financial institution of America began protection on shares of Day One Biopharmaceuticals in a report on Thursday, December 1st. They issued a “purchase” ranking and a $34.00 worth goal on the inventory. Needham & Firm LLC started protection on shares of Day One Biopharmaceuticals in a analysis observe on Wednesday, December 14th. They set a “purchase” ranking and a $40.00 worth goal for the corporate. Lastly, The Goldman Sachs Group started protection on Day One Biopharmaceuticals in a analysis report on Monday, December fifth. They set a “purchase” ranking and a $45.00 worth goal for the corporate. Six funding analysts have rated the inventory with a purchase ranking, In keeping with knowledge from MarketBeat, the corporate presently has a median ranking of “Purchase” and a consensus goal worth of $39.00.

Day One Biopharmaceuticals Inventory Efficiency

NASDAQ DAWN traded up $0.20 on Friday, hitting $21.34. 583,993 shares of the corporate’s inventory had been exchanged, in comparison with its common quantity of 462,840. The agency’s 50-day shifting common worth is $20.73 and its two-hundred day shifting common worth is $20.76. Day One Biopharmaceuticals has a fifty-two week low of $5.44 and a fifty-two week excessive of $28.35.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) final issued its earnings outcomes on Monday, November seventh. The corporate reported ($0.53) EPS for the quarter, hitting the consensus estimate of ($0.53). Analysis analysts count on that Day One Biopharmaceuticals will publish -2.18 EPS for the present 12 months.

Insider Exercise at Day One Biopharmaceuticals

In different information, Director Julie Papanek Grant bought 25,000 shares of the enterprise’s inventory in a transaction on Tuesday, January third. The shares had been bought at a median worth of $20.65, for a complete transaction of $516,250.00. Following the completion of the sale, the director now instantly owns 380,000 shares of the corporate’s inventory, valued at roughly $7,847,000. The sale was disclosed in a submitting with the Securities & Change Fee, which may be accessed by way of this link. In different information, Director Julie Papanek Grant bought 25,000 shares of the agency’s inventory in a transaction dated Tuesday, January third. The inventory was bought at a median worth of $20.65, for a complete worth of $516,250.00. Following the transaction, the director now instantly owns 380,000 shares within the firm, valued at roughly $7,847,000. The transaction was disclosed in a doc filed with the SEC, which is accessible by way of the SEC website. Additionally, CEO Jeremy Bender bought 12,500 shares of the enterprise’s inventory in a transaction dated Wednesday, December twenty first. The inventory was bought at a median worth of $20.32, for a complete worth of $254,000.00. Following the sale, the chief government officer now owns 1,192,424 shares of the corporate’s inventory, valued at roughly $24,230,055.68. The disclosure for this sale may be discovered here. Over the past three months, insiders bought 119,178 shares of firm inventory value $2,458,187. 8.70% of the inventory is owned by firm insiders.

Institutional Inflows and Outflows

Hedge funds and different institutional buyers have not too long ago modified their holdings of the inventory. Amalgamated Financial institution acquired a brand new place in shares of Day One Biopharmaceuticals throughout the first quarter value $30,000. ACG Wealth bought a brand new place in Day One Biopharmaceuticals within the 2nd quarter valued at about $32,000. TCI Wealth Advisors Inc. acquired a brand new stake in shares of Day One Biopharmaceuticals throughout the second quarter valued at about $35,000. Quantbot Applied sciences LP bought a brand new stake in shares of Day One Biopharmaceuticals throughout the second quarter value about $51,000. Lastly, UBS Group AG acquired a brand new place in shares of Day One Biopharmaceuticals within the second quarter value about $69,000. Institutional buyers and hedge funds personal 86.08% of the corporate’s inventory.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical firm, develops and commercializes focused therapies for sufferers with genetically outlined cancers. Its lead product candidate is DAY101, an oral brain-penetrant sort II pan-rapidly accelerated fibrosarcoma kinase inhibitor that’s in Part II scientific trial for pediatric sufferers with relapsed/progressive low-grade glioma.

Advisable Tales

The Fly logo

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

This immediate information alert was generated by narrative science expertise and monetary knowledge from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Day One Biopharmaceuticals, you may wish to hear this.

MarketBeat retains observe of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Day One Biopharmaceuticals wasn’t on the record.

Whereas Day One Biopharmaceuticals at the moment has a “Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments